10-Q: NexGel Inc. Reports Increased Revenue in First Quarter 2024, Driven by Branded Products and Contract Manufacturing

NexGel, Inc. saw a significant increase in revenue during the first quarter of 2024, primarily due to growth in both contract manufacturing and branded product sales.

Summary

• NexGel, Inc. reported a net revenue of $1.266 million for the three months ended March 31, 2024, a 104.2% increase compared to $620 thousand for the same period in 2023.
• The company's gross profit was $277 thousand, a significant improvement from a gross loss of $57 thousand in the first quarter of 2023.
• Operating expenses totaled $1.148 million, up from $826 thousand in the prior year, primarily due to increased selling, general, and administrative costs.
• The net loss attributable to NexGel stockholders was $853 thousand, compared to a net loss of $814 thousand in the first quarter of 2023.
• The company completed a registered direct offering (RDO) on February 15, 2024, raising net proceeds of $0.9 million.
• As of March 31, 2024, NexGel had a cash balance of $2.419 million and a working capital of $2.380 million.
• The company's inventory was valued at $1.369 million as of March 31, 2024.
• NexGel has two reportable segments: NexGel and CGN, with the NexGel segment focused on manufacturing hydrogel products and the CGN segment focused on converting and packaging.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and improved gross profit, which are positive indicators. However, the company is still incurring losses and has some risks, which temper the overall sentiment. The recent capital raise provides a buffer, but the need for future capital raises is a concern.

Positives

• The company experienced substantial revenue growth, more than doubling year-over-year.
• Gross profit improved significantly, moving from a loss to a profit.
• The recent capital raise provides additional financial stability.
• The company is expanding its product lines and sales channels.
• The company has a strong focus on developing a sales pipeline and expanding its customer base.

Negatives

• The company continues to incur net losses, although the loss was only slightly higher than the prior year.
• Operating expenses increased significantly, primarily due to increased selling, general, and administrative costs.
• The company's cash balance decreased slightly during the quarter.
• The company is still reliant on a small group of customers for a significant portion of its revenue.

Risks

• The company's ability to continue as a going concern is dependent on achieving profitable operations.
• The company may need to raise additional capital in the future.
• The company is subject to risks related to mergers and acquisitions.
• The company is exposed to risks related to competition and technological obsolescence.
• The company is reliant on a small group of customers for a significant portion of its revenue.
• The company is exposed to risks related to adverse economic conditions and government regulations.

Future Outlook

The company plans to continue building and developing its catalog of consumer products, develop proprietary medical devices, explore drug delivery programs, and evaluate strategic initiatives, including potential acquisitions and additional capital raises.

Management Comments

• Management is exploring new product channel sales in adjacent industries, such as cosmetics, athletic products, and proprietary medical devices.
• The Company has increased focus on sales and developing a sales pipeline for potential customers.
• We have sufficient capital to maintain as a going concern due to the recent capital raise.
• We intend to maintain and attempt to grow our existing contract manufacturing business.
• We also plan to continue building and developing our catalog of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products.
• Furthermore, the Company plans to develop its own proprietary medical devices and explore drug delivery programs for its technology.
• Additionally, the Company continues to evaluate strategic initiatives (e.g., acquisitions) and additional capital raises through debt or equity may be necessary to achieve these objectives.

Industry Context

The company operates in the healthcare and consumer products industries, focusing on hydrogel technology. The growth in branded consumer products aligns with the trend of direct-to-consumer sales and the increasing demand for specialized skincare and medical products. The company's expansion into medical devices and drug delivery programs positions it to capitalize on future growth opportunities in the medical technology sector.

Comparison to Industry Standards

• NexGel's revenue growth of 104.2% year-over-year is significantly higher than the average growth rate for companies in the medical device and consumer healthcare sectors, which typically see single-digit or low double-digit growth.
• The company's shift from a gross loss to a gross profit indicates improved operational efficiency and pricing strategies, which is a positive sign compared to industry peers that may struggle with profitability.
• While the company's net loss is still a concern, the improvement in gross profit and revenue growth suggests a potential path to profitability, which is a key metric for investors in the healthcare and consumer product industries.
• The company's focus on branded consumer products and custom manufacturing aligns with industry trends towards personalized and specialized products, which can provide a competitive advantage over companies that rely solely on mass-produced goods.
• The company's expansion into medical devices and drug delivery programs is a strategic move to diversify its revenue streams and tap into higher-margin markets, which is a common strategy among successful companies in the healthcare sector.
• Compared to companies like 3M, which also produces medical and consumer products, NexGel is still in an early growth phase, but its focus on specialized hydrogel technology and custom manufacturing could allow it to carve out a niche market.

Related Party Transactions

• Dr. Jerome Zeldis, a member of the Company board of directors, has an outstanding balance due of $25,000 for services as of March 31, 2024 and December 31, 2023, included in accounts payable.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and improved gross profit, but will be concerned about the continued net losses and potential need for future capital raises.
• Employees may see increased job security due to the company's growth and expansion.
• Customers will benefit from the company's expanded product lines and improved manufacturing capabilities.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors will be concerned about the company's continued net losses and potential need for future capital raises.

Next Steps

• The company plans to continue building and developing its catalog of consumer products.
• The company plans to develop its own proprietary medical devices.
• The company plans to explore drug delivery programs for its technology.
• The company will continue to evaluate strategic initiatives, including potential acquisitions.
• The company may consider additional capital raises through debt or equity offerings.

Key Dates

Keywords

hydrogels, contract manufacturing, branded consumer products, medical devices, revenue growth, gross profit, registered direct offering, working capital, Kenkoderm, joint venture